At $850000, price for new childhood blindness gene therapy four times too high, analysis says – PBS NewsHour
PBS NewsHour |
At $850000, price for new childhood blindness gene therapy four times too high, analysis says
PBS NewsHour While Luxturna is a one-time therapy, it does not “cure” people born with mutated RPE65 genes; instead, it is meant to stop disease progression and restore some visual strength. But other gene therapies in pipelines could, by replacing faulty genes … Spark's price for Luxturna blindness gene therapy too high: ICER |
